✦ LIBER ✦

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

✍ Scribed by Tripathy, D.

Book ID: 123564656
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 174 KB
Volume: 20
Category: Article
ISSN: 1043-321X
DOI: 10.1016/S1043-321X(09)79440-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Time to first tumor progression as a pre

Time to first tumor progression as a predictor of efficacy of continued treatment with trastuzumab beyond progression in human epidermal growth factor receptor 2-positive metastatic breast cancer

✍ Mitsuhiro Hayashi; Yasuhiro Okumura; Tomofumi Osako; Yasuo Toyozumi; Nobuyuki Ar 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 215 KB

Phase II Randomized Study of Trastuzumab

Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer

✍ Hurvitz, S. A.; Dirix, L.; Kocsis, J.; Bianchi, G. V.; Lu, J.; Vinholes, J.; Gua 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 205 KB

Pertuzumab Monotherapy After Trastuzumab

Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

✍ Cortes, J.; Fumoleau, P.; Bianchi, G. V.; Petrella, T. M.; Gelmon, K.; Pivot, X. 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 497 KB

A phase 1 study of weekly dosing of tras

A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer

✍ Muralidhar Beeram; Ian E. Krop; Howard A. Burris; Sandhya R. Girish; Wei Yu; Mic 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 417 KB

Erratum to: Trastuzumab: a review of its

Erratum to: Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer

✍ KP Garnock-Jones, GM Keating, LJ Scott 📂 Article 📅 2011 🏛 Springer International Publishing AG 🌐 English ⚖ 49 KB

Clinicopathological Features Among Patie

Clinicopathological Features Among Patients With Advanced Human Epidermal Growth Factor–2-Positive Breast Cancer With Prolonged Clinical Benefit to First-Line Trastuzumab-Based Therapy: A Retrospective Cohort Study

✍ Vaz-Luis, Ines; Seah, Davinia; Olson, Erin M.; Wagle, Nikhil; Metzger-Filho, Ott 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 652 KB